Patents by Inventor Meromit Singer

Meromit Singer has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220105135
    Abstract: The present invention is generally directed to identifying genes and cell types that are correlated with tumor progression in the tumor microenvironment. PENK was identified as a therapeutic target that is positively correlated with tumor time and size. Targeting PENK can enhance anti-tumor immunity. Opioid signaling can be modulated to enhance anti-tumor immunity. The present invention is also generally directed to interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer.
    Type: Application
    Filed: October 5, 2021
    Publication date: April 7, 2022
    Inventors: Meromit Singer, Aviv Regev, Orit Rozenblatt-Rosen, Davide Mangani, Ana Carrizosa Anderson, Vijay K. Kuchroo, Linglin Huang
  • Patent number: 11186825
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 30, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Patent number: 11180730
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and/or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: November 23, 2021
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, The Brigham and Women's Hospital, Inc.
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Publication number: 20210263012
    Abstract: The subject matter disclosed herein is generally directed to novel CD8+ and CD4+ T cell subtypes associated with effector, suppressive or regulatory T cell functions. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the subtype. Also, disclosed herein are gene signatures and markers associated with the subtype and use of said signatures and markers. Further disclosed are therapeutic methods of using said gene signatures and immune cell subtype. Further disclosed are pharmaceutical compositions comprising populations of CD4+ and/or CD8+ TILs or populations of immune cells depleted for a specific subtype. Further disclosed are interactions with other T cell subtypes.
    Type: Application
    Filed: November 19, 2018
    Publication date: August 26, 2021
    Inventors: Ana C. Anderson, Vijay K. Kuchroo, Meromit Singer, Aviv Regev
  • Publication number: 20210130776
    Abstract: The subject matter disclosed herein is generally directed to a novel CD8+ T cell subtype associated with suppressive or regulatory T cell functions. Moreover, the subject matter disclosed herein is generally directed to methods and compositions for use of the subtype. Also, disclosed herein are gene signatures and markers associated with the subtype and use of said signatures and markers. Further disclosed are therapeutic methods of using said gene signatures and immune cell subtype. Further disclosed are pharmaceutical compositions comprising populations of CD8+ TILs depleted for a specific subtype. Further disclosed are interactions with other T cell subtypes.
    Type: Application
    Filed: October 1, 2018
    Publication date: May 6, 2021
    Inventors: Ana Carrizosa Anderson, Vijay K. Kuchroo, Meromit Singer, Aviv Regev
  • Publication number: 20210102166
    Abstract: The subject matter disclosed herein is generally directed to tissue specific modulation of Th17 differentiation and pathogenicity by targeting tissue specific Th17 gene programs and gene targets. The tissue specific modulation may be used therapeutically to treat a disease or condition in the tissue where it arises. The subject matter disclosed herein is also directed to detecting tissue specific Th17 cells for diagnostic and therapeutic methods.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Inventors: Meromit Singer, Alexandra Schnell, Aviv Regev, Vijay K. Kuchroo
  • Publication number: 20210102168
    Abstract: The present invention is generally directed to identify interacting cells in the tumor microenvironment and using the identified interactions to enhance anti-tumor immunity in cancer. Identified interactions can be modulated using therapeutic agents. Immune cells resistant to suppression can be used for adoptive cell transfer. The present invention is also generally directed to cell types and genes that are correlated to time of tumor growth and tumor size.
    Type: Application
    Filed: October 5, 2020
    Publication date: April 8, 2021
    Inventors: Meromit Singer, Aviv Regev, Orit Rozenblatt-Rosen, Davide Mangani, Ana Carrizosa Anderson, Vijay K. Kuchroo, Linglin Huang
  • Publication number: 20200016202
    Abstract: Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network and novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module.
    Type: Application
    Filed: October 6, 2017
    Publication date: January 16, 2020
    Applicants: The Brigham and Women's Hospital, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Vijay K. KUCHROO, Ana Carrizosa ANDERSON, Asaf MADI, Norio CHIHARA, Aviv REGEV, Meromit SINGER, Huiyuan ZHANG
  • Publication number: 20190262399
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction or activation of immune cells. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from a modulated immune response.
    Type: Application
    Filed: September 7, 2017
    Publication date: August 29, 2019
    Inventors: Chao Wang, Meromit Singer, Aviv Regev, Vijay K. Kuchroo
  • Publication number: 20190255107
    Abstract: Dysfunctional or exhausted T cells arise in chronic diseases including chronic viral infections and cancer, and express high levels of co-inhibitory receptors. Therapeutic blockade of these receptors has clinical efficacy in the treatment of cancer. While co-inhibitory receptors are co-expressed, the triggers that induce them and the transcriptional regulators that drive their co-expression have not been identified. The immunoregulatory cytokine IL-27 induces a gene module in T cells that includes several known co-inhibitory receptors (Tim-3, Lag-3, and TIGIT). The present invention provides a novel immunoregulatory network as well as novel cell surface molecules that have an inhibitory function in the tumor microenvironment. The present invention further provides the novel discovery that the transcription factors Prdm1 and c-Maf cooperatively regulate the expression of the co-inhibitory receptor module.
    Type: Application
    Filed: October 7, 2016
    Publication date: August 22, 2019
    Applicants: The Brigham and Women's Hospital, Inc., The Broad Institute, Inc., Massachusetts Institute of Technology
    Inventors: Vijay K. KUCHROO, Ana C. ANDERSON, Asaf MADI, Norio CHIHARA, Aviv REGEV, Meromit SINGER
  • Publication number: 20190106679
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, GATA3 and/or FOXO1 modulation are provided for use as markers, marker signatures and molecular targets. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Application
    Filed: April 30, 2018
    Publication date: April 11, 2019
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Publication number: 20190106678
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Specifically, POU2AF1 modulation is provided for use as a marker, marker signature and molecular target. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Application
    Filed: April 30, 2018
    Publication date: April 11, 2019
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang
  • Publication number: 20190100801
    Abstract: The present invention provides markers, marker signatures and molecular targets that correlate with dysfunction of immune cells and are advantageously independent of the immune cell activation status. The present markers, marker signatures and molecular targets provide for new ways to evaluate and modulate immune responses. Therapeutic methods are also provided to treat a patient in need thereof who would benefit from an increased immune response.
    Type: Application
    Filed: April 30, 2018
    Publication date: April 4, 2019
    Inventors: Aviv Regev, Ana Carrizosa Anderson, Le Cong, Vijay K. Kuchroo, Meromit Singer, Chao Wang